oronary heart disease (CHD) is still a major worldwide threat to health. 1 Although several risk factors contribute to CHD, low-density lipoprotein-cholesterol (LDL-C) is a major risk factor. 2 Several clinical trials indicate that for every 1% reduction in LDL-C level, the relative risk for a major CHD event is reduced by approximately 1%. [3] [4] [5] [6] [7] [8] [9] [10] [11] Recently, more and more clinical trials have proved CHD patients, or equivalent high-risk status patients, could benefit from lowering of the LDL-C level with statins. Recent clinical trials, 12-16 such as HPS and PROVE-IT- 3, 17 showed further benefit could be achieved by more aggressive LDL-C lowering to well below 100 mg/dl in some patient populations. Based on these recent trials, an LDL-C goal of <70 mg/dl (1.82 mmol/L) is the recommended therapeutic option for high-risk CHD patients, and <100 mg/dl (2.6 mmol/L) is a strong recommendation. The purpose of this study was to investigate the treatment of outpatients with CHD, especially with statins, and the rates of achieving the guideline goals in China.
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Dayi Hu, MD, FACC; Jue Li, MD, PhD; Xiankai Li, MD for the China Cholesterol Education Program risk equivalents such as non-coronary forms of atherosclerotic disease [peripheral arterial disease (PAD), abdominal aortic aneurysm, and carotid artery disease (transient ischemic attacks or stroke of carotid origin or >50% obstruction of a carotid artery)], and diabetes mellitus (DM).
Patients at very high risk were those with established cardiovascular disease plus (1) multiple major risk factors (especially DM), (2) severe and poorly controlled risk factors (eg, continued cigarette smoking), (3) multiple risk factors of the metabolic syndrome (triglycerides (TG) ≥200 mg/dl plus non-high-density lipoprotein-cholesterol (HDL-C) ≥130 mg/dl with low HDL-C <40 mg/dl), and (4) ACS.
Other Criteria
Hypertension was defined as systolic blood pressure ≥140 mmHg, and/or diastolic blood pressure ≥90 mmHg, and/or current antihypertensive medication. 18 DM was defined as: (1) fasting plasma glucose concentration >7.0 mmol/L in the absence of treatment; (2) fasting plasma glucose concentration ≥11.0 mmol/L, 2 h after a 75-g oral glucose load; or (3) current treatment with hypoglycemic drugs. 19 Ischemic stroke was defined as a history of physician-diagnosed cerebral attack or self-reporting of a prior cerebral revascularization procedure. PAD was defined as partial or complete atherosclerotic obstruction of the peripheral arteries on angiography, or intermittent claudication. 20 Dyslipidemia was defined as total cholesterol (TC) ≥5.2 mmol/L, and/or HDL-C ≤0.9 mmol/L, and/or LDL-C ≥3.12 mmol/L, and/or TG ≥1.69 mmol/L, or undergoing current lipid-lowering treatment. Smoking was considered positive in those who smoked at least 1 cigarette/day for at least 1 year.
The data collection protocol was approved by the Beijing University Research Ethics Committee. All participants signed informed consent statements allowing access to their medical records.
Statistical Analysis
All case record form data were entered into dual Epidata 3.02 databases by different people. The 2 databases were compared and any necessary corrections were made. All analyses were performed with the Statistics Package for Social Science, version 13.0 (Chicago, IL, USA). Continuous variables are expressed as mean ± SD, and discrete varia- 
Results

Recruitment
Case record forms were collected for 4,861 patients; 83 patients were excluded because of protocol violations and abnormal laboratory examination results (eg, AST or ALT levels ≥3-fold the upper limit of normal). The eligible 4,778 patients were divided into 2 groups according to risk category.
Baseline Characteristics
The baseline demographics of the CHD outpatients are shown in Table 1 . More of the participants were male (64%). The average age was 62 years. Most CHD occurred in the patients between the ages of 65 and 75 years (35.4%); 24.2% of the outpatients had a family history of premature CHD. Table 1 also shows the disease history of the participants. The most frequent disease was dyslipidemia (78.5%), although hypertension was also common (68.9%). The mean LDL-C level was 2.93±1.00 mmol/L. Statins were prescribed in 82.2% of the outpatients. Table 2 shows the baseline laboratory results. The outpatients at high risk had a higher TC level than those at very high risk (5.06±1.52 mmol/L vs 4.91±1.52 mmol/L, p=0.003). The baseline levels of HDL-C and LDL-C in outpatients at high risk were significantly higher than the levels in those at very high risk (p<0.001), although the reverse was true for glucose, ALT, CK, hemoglobin A1c, and SCr. Table 3 illustrates the baseline medical interventions. There was no significant difference between the 2 risk groups for the proportion of patients taking statins (81.4% vs 82.5%, p=0.382).
Statin therapy and the percentage of patients achieving the target LDL-C level are shown in Table 4 (all statins listed are generic). Of the 1,171 patients at high risk, 81.4% were taking statins as lipid-lowering therapy; statins were also used in 82.5% of the 3,607 patients at very high risk (Fig 1) . Table 4 and Fig 1 illustrate that only 36 Table 1 for abbreviation.
Table 4 Statin Therapy and Percentage of Patients Achieving the Target LDL-C Level
LDL-C <2.6 mmol/L is the target level for high-risk patients; LDL-C <1.82 mmol/L is the goal for very-high-risk patients. See
high-risk outpatients achieved the target LDL-C level (<2.6 mmol/L); 10.9% of the very-high-risk outpatients achieved the optimal LDL-C level (<1.82 mmol/L) as suggested by NCEP ATPIII. 21 Achievement rates with different statins were also investigated. There was no significance in the rate of achievement among the statins in either the high-risk or very-high-risk patients. The rate of achieving the target level was only 42.2%, even though the LDL-C <2.6 mmol/L was the goal for patients at very high risk.
Discussion
Many clinical trials of statin therapy have been published. [3] [4] [5] [6] [7] [8] [9] 11, 14 NCEP reviewed the results of the major trials and assesses their implications for cholesterol management. They recommend the LDL-C goal of <100 mg/dl in highrisk persons, but when the risk is very high, an LDL-C goal of <70 mg/dl is a therapeutic option. 21 China has also updated its guideline for the treatment of dyslipidemia in CHD patients. 22 This is the first, large multicenter study with systematic availability of medical records surveying lipid level and statin interventions in CHD outpatients in China. It may well represent the situation in many areas of China. LDL-C is an independent risk factor for CHD [23] [24] [25] and the CCEP survey revealed the average LDL-C level in the participants was 2.93 mmol/L, which is higher than the 2.6 mmol/L suggested by NCEP ATPIII. Therefore, statins should be prescribed for Chinese CHD patients, besides their benefit of lipid lowering. [26] [27] [28] [29] [30] In this study, 82.2% of the participants received statin therapy, which was higher than a result from Japan (36.3%) 31 and from Hong Kong where a report showed that only 37% of participants received lipid-lowering drugs. 32 It is also higher than the results of small trials in China and other reports. 33 In other words, Chinese medical practitioners have realized that lowering LDL-C is the basic treatment for patients with CHD.
We are curious why the LDL-C level was higher in outpatients with high risk than in those with very high risk ( Table 2 ). The probable reason is that outpatients at very high risk knew the dangers of their disease, paid more attention to their health and their compliance was good, including with the advice given by doctors. It is also possible that the patients were on higher doses of statins or taking a more potent statin. The total effect of these differences might have contributed to the lower LDL-C level in these patients.
The outpatients also implemented lifestyle changes and received antiplatelet drugs, ACEIs, statins, etc. Both highrisk and very-high-risk patients had higher rates of statin interventions. Most Chinese medical practitioners knew the benefit of statin therapy, so the rate of statin interventions was much higher.
Although most of the outpatients in both the high-risk and very-high-risk groups received lipid-lowering therapy, only 36.2% of the high-risk outpatients reached the target LDL-C level (2.6 mmol/L), and only 10.9% of the veryhigh-risk outpatients achieved their goal (1.82 mmol/L). The rate of achieving the target was only 42.2%, even though LDL-C <2.6 mmol/L was the target level for patients at very high risk. A report from Japan shows the rate of achieving the target level in patients with CHD was 29.9%; 31 and the rate was only 15% in patients with coronary artery disease in Hong Kong. 32 Our result was also higher according to NCEP ATPIII compared with other low reported rates of success in achieving NCEP goal. 34 However, all the success rates were much lower. The NCEP report has been accepted by most Chinese medical practitioners in recent years; however, there is still a significant gap between the guidelines and clinical practice. The possible reasons are that physicians paid more attentions to the outpatients, but there was not good follow-up for the LDL-C level. The duration of the statin intervention may be shorter than 6 weeks for outpatients who first consulted a doctor. Different statins have different effects in lowering LDL-C and some may have not been appropriate for some of the outpatients. All the doses of statins were moderate, so maybe more intensive LDL-C therapy should have been used in those outpatients who did not achieve the goals. Though the LDL-C level was higher than the goals, maybe the reduction in the LDL-C level was larger than 30% in some outpatients; and the adherence of outpatients to therapy should also be investigated. Another question is whether Chinese medical practitioners are hesitant to prescribe statins or give intensive statins intervention because of the safety issue regarding these drugs.
Study limitations
Firstly, this was a cross-sectional study and only represents larger cities in China. Secondly, the rates of achieving the targets were low and the exact reasons for this were not found, although there are several possible explanations. Rates of treatment and achieving the target low-density lipoprotein-cholesterol level using statins in patients at high risk and very high risk of coronary heart disease.
